Investor Relations

Corporate Profile

PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products. The PLxGuard™  drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx Pharma believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

Stock Quote

Exchange
Volume
Today's Open
Previous Close

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

Recent News

Date Title
03/01/21
Summary TogglePLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg
-- VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications – -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- SPARTA, N.J.
11/16/20
Summary TogglePLx Pharma Inc. Reports Third Quarter 2020 Results and Provides Business Update
--Announces $18 million private placement-- --Submitted sNDAs for VAZALORE 325 mg and 81 mg doses to FDA end of October-- --On target for third quarter 2021 commercial launch of VAZALORE-- SPARTA, N.J. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
11/16/20
Summary TogglePLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration
-- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 – SPARTA, N.J. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP), a late-stage specialty pharmaceutical company focused on its clinically-validated

Upcoming Events

There are currently no events to display.

References: 1. Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin–phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272-277. 2. Bhatt DL, Grosser T, Dong JF, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. JACC. 2017;69(6):603-612.